Celltrion Inc - Asset Resilience Ratio
Celltrion Inc (068270) has an Asset Resilience Ratio of 0.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Celltrion Inc's Asset Resilience Ratio has changed over time. Check how strategically is Celltrion Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Celltrion Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Celltrion Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩129.99 Billion | 0.56% |
| Total Liquid Assets | ₩129.99 Billion | 0.56% |
Asset Resilience Insights
- Limited Liquidity: Celltrion Inc maintains only 0.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Celltrion Inc Industry Peers by Asset Resilience Ratio
Compare Celltrion Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
INVENTIVA ADS/1 O.N.
F:6IVA |
Biotechnology | 52.73% |
|
Medincell SA
PA:MEDCL |
Biotechnology | 45.63% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
Annual Asset Resilience Ratio for Celltrion Inc (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Celltrion Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.54% | ₩119.90 Billion ≈ $81.25 Million |
₩22.33 Trillion ≈ $15.14 Billion |
-0.16pp |
| 2024-12-31 | 0.70% | ₩146.61 Billion ≈ $99.36 Million |
₩21.06 Trillion ≈ $14.27 Billion |
-0.27pp |
| 2023-12-31 | 0.97% | ₩192.89 Billion ≈ $130.72 Million |
₩19.92 Trillion ≈ $13.50 Billion |
+0.23pp |
| 2022-12-31 | 0.73% | ₩43.28 Billion ≈ $29.33 Million |
₩5.89 Trillion ≈ $3.99 Billion |
+0.18pp |
| 2021-12-31 | 0.56% | ₩31.57 Billion ≈ $21.40 Million |
₩5.67 Trillion ≈ $3.85 Billion |
+0.28pp |
| 2020-12-31 | 0.28% | ₩14.03 Billion ≈ $9.51 Million |
₩5.02 Trillion ≈ $3.40 Billion |
-1.84pp |
| 2019-12-31 | 2.12% | ₩81.68 Billion ≈ $55.35 Million |
₩3.86 Trillion ≈ $2.62 Billion |
-1.36pp |
| 2018-12-31 | 3.47% | ₩121.64 Billion ≈ $82.43 Million |
₩3.50 Trillion ≈ $2.37 Billion |
-0.74pp |
| 2017-12-31 | 4.21% | ₩138.72 Billion ≈ $94.01 Million |
₩3.29 Trillion ≈ $2.23 Billion |
+4.02pp |
| 2016-12-31 | 0.19% | ₩5.77 Billion ≈ $3.91 Million |
₩3.02 Trillion ≈ $2.05 Billion |
-0.03pp |
| 2015-12-31 | 0.22% | ₩6.00 Billion ≈ $4.07 Million |
₩2.75 Trillion ≈ $1.86 Billion |
-1.08pp |
| 2014-12-31 | 1.30% | ₩30.15 Billion ≈ $20.43 Million |
₩2.32 Trillion ≈ $1.57 Billion |
-0.34pp |
| 2013-12-31 | 1.64% | ₩32.38 Billion ≈ $21.94 Million |
₩1.98 Trillion ≈ $1.34 Billion |
-1.25pp |
| 2012-12-31 | 2.89% | ₩50.01 Billion ≈ $33.89 Million |
₩1.73 Trillion ≈ $1.17 Billion |
+2.22pp |
| 2011-12-31 | 0.66% | ₩9.36 Billion ≈ $6.34 Million |
₩1.41 Trillion ≈ $953.72 Million |
-7.45pp |
| 2010-12-31 | 8.12% | ₩93.81 Billion ≈ $63.58 Million |
₩1.16 Trillion ≈ $783.04 Million |
+7.07pp |
| 2009-12-31 | 1.05% | ₩5.88 Billion ≈ $3.98 Million |
₩559.20 Billion ≈ $378.96 Million |
+0.27pp |
| 2008-12-31 | 0.78% | ₩3.89 Billion ≈ $2.64 Million |
₩499.26 Billion ≈ $338.34 Million |
-3.48pp |
| 2007-12-31 | 4.25% | ₩2.62 Billion ≈ $1.77 Million |
₩61.46 Billion ≈ $41.65 Million |
-- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more